Tumor suppressors associated with human chromosome 21q22
AssigneeThe Brigham and Women's Hospital, Inc.
InventorMarkus H. Frank
Life of this patent
Estimating the term…
Abstract
The present invention is directed to tumor suppressor polypeptides and to polynucleotide sequences by which they are encoded. It includes assays designed for detecting mutations that predispose a patient to certain forms of cancer and therapeutic methods in which suppressor proteins or genes encoding the proteins are administered to patients.
Claims27
A substantially pure protein consisting essentially of the amino acid sequence of SEQ ID NO:
- 1.
An isolated polynucleotide consisting essentially of the nucleotide sequence of SEQ ID NO:
- 4.
A substantially pure protein consisting essentially of the amino acid sequence of SEQ ID:
- 2.
An isolated polynucleotide consisting essentially of the nucleotide sequence of SEQ ID NO:
- 5.
A substantially pure peptide consisting essentially of the amino acid sequence of SEQ ID NO:
- 3.
An isolated polynucleotide consisting essentially of the nucleotide sequence of SEQ ID NO:
- 6.
An assay for determining whether a subject has a predisposition to develop cancer comprising:
- (a) obtaining a cell or tissue sample from said patient;
- and
- (b) determining whether nucleic acid derived from said cell or tissue sample has a mutation that would affect the biological activity of a polypeptide selected from the group consisting of:
- SEQ ID NO:
- 1;
- SEQ ID NO:
- 2;
- and SEQ ID NO:
- 3.
A method of treating a patient for cancer, comprising administering to said patient the peptide of SEQ ID NO:
- 3 at a dosage sufficient to retard the growth of cancer cells.
Dependencies are inferred from the claim text.